These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15060190)

  • 1. Pediatric pharmacokinetic data: implications for environmental risk assessment for children.
    Ginsberg G; Hattis D; Miller R; Sonawane B
    Pediatrics; 2004 Apr; 113(4 Suppl):973-83. PubMed ID: 15060190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants.
    Ginsberg G; Hattis D; Sonawane B
    Toxicol Appl Pharmacol; 2004 Jul; 198(2):164-83. PubMed ID: 15236952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilization of juvenile animal studies to determine the human effects and risks of environmental toxicants during postnatal developmental stages.
    Brent RL
    Birth Defects Res B Dev Reprod Toxicol; 2004 Oct; 71(5):303-20. PubMed ID: 15505806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents.
    Ginsberg G; Hattis D; Russ A; Sonawane B
    J Toxicol Environ Health A; 2004 Feb; 67(4):297-329. PubMed ID: 14713563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of animal studies to determine the effects and human risks of environmental toxicants (drugs, chemicals, and physical agents).
    Brent RL
    Pediatrics; 2004 Apr; 113(4 Suppl):984-95. PubMed ID: 15060191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of biokinetics in risk assessment of drugs and chemicals in children.
    de Zwart LL; Haenen HE; Versantvoort CH; Wolterink G; van Engelen JG; Sips AJ
    Regul Toxicol Pharmacol; 2004 Jun; 39(3):282-309. PubMed ID: 15135209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing pediatric dosing: a developmental pharmacologic approach.
    Anderson GD; Lynn AM
    Pharmacotherapy; 2009 Jun; 29(6):680-90. PubMed ID: 19476420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk assessment of chemicals and pharmaceuticals in the pediatric population: a workshop report.
    Pohl HR; van Engelen JG; Wilson J; Sips AJ
    Regul Toxicol Pharmacol; 2005 Jun; 42(1):83-95. PubMed ID: 15896447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applicability of the principles of developmental pharmacology to the study of environmental toxicants.
    McCarver DG
    Pediatrics; 2004 Apr; 113(4 Suppl):969-72. PubMed ID: 15060189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating children's toxicokinetics into a risk framework.
    Ginsberg G; Slikker W; Bruckner J; Sonawane B
    Environ Health Perspect; 2004 Feb; 112(2):272-83. PubMed ID: 14754583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic investigation of actinomycin-D in children and young adults.
    Mondick JT; Gibiansky L; Gastonguay MR; Skolnik JM; Cole M; Veal GJ; Boddy AV; Adamson PC; Barrett JS
    J Clin Pharmacol; 2008 Jan; 48(1):35-42. PubMed ID: 18094218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developmental pharmacology.
    van den Anker JN
    Dev Disabil Res Rev; 2010; 16(3):233-8. PubMed ID: 20981761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal clearance parameters for PBPK model analysis of early lifestage differences in the disposition of environmental toxicants.
    DeWoskin RS; Thompson CM
    Regul Toxicol Pharmacol; 2008 Jun; 51(1):66-86. PubMed ID: 18433959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescribing for children: issues in pediatric pharmacology.
    Niederhauser VP
    Nurse Pract; 1997 Mar; 22(3):16-8, 23, 26-8 passim. PubMed ID: 9078512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational pharmacokinetics during developmental windows of susceptibility.
    Barton HA
    J Toxicol Environ Health A; 2005 Jun 11-25; 68(11-12):889-900. PubMed ID: 16020183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: a case study with toluene.
    Nong A; McCarver DG; Hines RN; Krishnan K
    Toxicol Appl Pharmacol; 2006 Jul; 214(1):78-87. PubMed ID: 16464483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study.
    Veal GJ; Cole M; Errington J; Parry A; Hale J; Pearson AD; Howe K; Chisholm JC; Beane C; Brennan B; Waters F; Glaser A; Hemsworth S; McDowell H; Wright Y; Pritchard-Jones K; Pinkerton R; Jenner G; Nicholson J; Elsworth AM; Boddy AV;
    Clin Cancer Res; 2005 Aug; 11(16):5893-9. PubMed ID: 16115931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Databases applicable to quantitative hazard/risk assessment--towards a predictive systems toxicology.
    Waters M; Jackson M
    Toxicol Appl Pharmacol; 2008 Nov; 233(1):34-44. PubMed ID: 18675838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonidine disposition in children; a population analysis.
    Potts AL; Larsson P; Eksborg S; Warman G; Lönnqvist PA; Anderson BJ
    Paediatr Anaesth; 2007 Oct; 17(10):924-33. PubMed ID: 17767627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.